IL-9

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Retrieved on: 
Monday, March 25, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Itolizumab, Organic acid, Harvard Medical School, Exercise, Alopecia areata, ASN, Partnership, Patient, Gastrointestinal tract, ACR, IL-9, Acquisition, G&A, MPA, Dermatology, Investment, MPH, Therapy, Eosinophilic esophagitis, Retirement, Inflammatory bowel disease, Lupus nephritis, JAK, Pharmaceutical industry

Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.

Key Points: 
  • Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $9.2 million, compared with $8.5 million for the same period in 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $3.2 million, compared with $5.2 million for the same period in 2022.
  • Net cash used in operating activities in the fourth quarter was $5.7 million.

Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Private Securities Litigation Reform Act, Head, Forward-looking statement, Prevalence, Adult, Alopecia totalis, Risk, University, IL-9, Depression, Nasdaq, Peptide, Cytokine, EDGAR, World Congress on Communication for Development, Anxiety, Thyroiditis, MCP, Incidence, Drug development, Face, SEC, Man, Alopecia areata, Safety, Dermatology, Degenerative disease, Hair loss, Alopecia universalis, Autoimmunity, Biomarker, Disease, JAK, Vitiligo, Patient, Immune system, 2009 Davis Cup, Woman, Therapy, Scalp, CTCL, Inflammation, Congress, Itolizumab, Trial of the century, Pharmaceutical industry, Vaccine, AA, Medicine

We believe this study will benefit from strong enrollment support and look forward to presenting data from this study next year.

Key Points: 
  • We believe this study will benefit from strong enrollment support and look forward to presenting data from this study next year.
  • Alopecia areata is one of the most common auto-immune diseases in man with a lifetime risk of two percent.
  • Equillium is currently enrolling patients in a Phase 2 proof-of-concept study of EQ101 for patients with alopecia areata.
  • Equillium is currently enrolling patients in a Phase 1 study of EQ102, including healthy volunteers and celiac disease patients.

Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit

Retrieved on: 
Thursday, November 3, 2022
Research, Public Relations, Investor Relations, Clinical Trials, Communications, Biotechnology, General Health, Health, Science, Oncology, Other Science, Technology, Cytokine, Private Securities Litigation Reform Act, Therapy, Risk, EDGAR, IL-9, Multi, Safety, MCI, Toxic shock syndrome, Hair loss, Trial of the century, Nasdaq, Boston Park Plaza, Degenerative disease, MCP, Inflammation, Itolizumab, Peptide, Forward-looking statement, Drug development, Cutaneous T cell lymphoma, Summit, Feedback, JAK, SEC, Autoimmunity, Patient, Alopecia areata, CTCL, Pharmaceutical industry, Vaccine

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 6th Annual Dermatology Drug Development Summit.

Key Points: 
  • Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 6th Annual Dermatology Drug Development Summit.
  • The presentation highlights Equilliums Multi-Cytokine Inhibitor EQ101 as a novel molecular compound to treat alopecia areata.
  • Responsible for the signaling of more than 50 cytokines, the JAK/STAT pathways have become key targets for drug development, with multiple JAK inhibitors approved over the last decade.
  • The presentation is available on the Multi-Cytokine tab of the Presentations page under the Technology section of the company website.

AAFD announces 2022 TQF Lifetime Achievement Award to Ron Gardner and the Robert L. Purvin Legacy Award to Keith Miller

Retrieved on: 
Monday, July 25, 2022
Dady, Association, Total quality management, Capitol Hill, American Association of Franchisees and Dealers, Industry, Franchise Rule, Legislation, PALM, American Bar Association, Ear, Magic, Unit, IL-9, List of lifetime achievement awards, American Association, Federal Trade Commission, AAFD, Leadership, TQF, Miller, Business rules engine, Video game

PALM DESERT, Calif., July 25, 2022 /PRNewswire-PRWeb/ -- American Association of Franchisees and Dealers (AAFD), a national trade association advocating for franchisees and independent dealers, today announced the recipients of the AAFD Total Quality Franchising® (TQF) Lifetime Achievement Award and Robert L. Purvin Legacy Award recipients for 2022. Attorney Ron Gardner will be recognized with the TQF Lifetime Achievement Award. Keith Miller will be presented with the Robert Purvin TQF Legacy Award. The honors will be presented at the AAFD's Total Quality Franchising® Awards ceremony on September 12th during the AAFD's annual Franchisee Leadership Summit, September 10-13, in Mesa, Arizona.

Key Points: 
  • Keith Miller will be presented with the Robert Purvin TQF Legacy Award.
  • Attorney Ron Gardner will be recognized with the TQF Lifetime Achievement Award.
  • "The AAFD is honored to present Attorney Ron Gardner with the Total Quality Franchising Lifetime Achievement Award," said Robert Purvin, AAFD chief executive officer and chairman.
  • "The AAFD, and I personally, am honored and privileged to recognize Ron Gardner with the AAFD's TQF Award for Lifetime Achievement.

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Retrieved on: 
Thursday, April 28, 2022
PD-1, Squamous cell carcinoma, ASCO, Program, IL-9, LinkedIn, Cancer, Patient, Twitter, IL-2, GLOBE, Aryl hydrocarbon receptor, Annual general meeting, Factor X, NF2, Private Securities Litigation Reform Act, American Society of Clinical Oncology, RAS, Clinical trial, BMS, AHR, Abstract (summary), Immunology, Standard of care, Nivolumab, EHE, Tumor microenvironment, Cytokine, Kynurenine, Bristol Myers Squibb, Society, Hippopotamus, TAZ, SEC, TEAD, Pharmaceutical industry

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.
  • The presentations will include overviews of the clinical trials for Ikenas novel TEAD inhibitor, IK-930, and aryl hydrocarbon receptor (AHR) antagonist, IK-175.
  • BMS has the right to exclusively license the program through the completion of the Phase 1b portion of the clinical trial.
  • Ikena OncologyTM is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175

Retrieved on: 
Friday, November 12, 2021
AHR, Safety, SITC, Bladder cancer, Kynurenine, Cancer, Ligand, Squamous cell carcinoma, IL-2, Hippopotamus, CLIA, Neoplasm, Cytokine, Clinical trial, RAS, Method, RNA, IL-9, Immune system, Society, Nivolumab, BMS, Aryl hydrocarbon receptor, Standard of care, Tumor microenvironment, PD-1, Program, Society for Immunotherapy of Cancer, Annual general meeting, GLOBE, Immunology, Immunotherapy, Survival, TEAD, Prevalence, Cell, Adult, Bristol Myers Squibb, Pharmaceutical industry, Vaccine, Medical imaging

BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced data from multiple presentations at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting from their IK-175 AHR antagonist program. The ongoing IK-175 clinical trial is currently recruiting patients in both monotherapy and combination cohorts with nivolumab.

Key Points: 
  • AHR is a transcription factor that facilitates tumor progression by allowing cancer cells to evade the immune system.
  • Cancer cells release multiple different AHR ligands, including kynurenine, activating the pathway and fostering an immunosuppressive effect within the tumor microenvironment.
  • The data presented at SITC speak to the robust translational approaches we employ across the entirety of our portfolio.
  • Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program

Retrieved on: 
Monday, October 25, 2021
Lung, University College London, T helper cell, Dexamethasone, Inflammation, Thrombotic microangiopathy, Failure, UCL, Leukotriene, Drug development, European Medicines Agency, IL-9, UCL Institute of Ophthalmology, Pathology, C5a, EMA, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, FDA, LTB4, Food, SEC, Eye, Risk, University college, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Moorfields Eye Hospital, BP, TMA, Steroid, Leukotriene B4, VKC, Biomarker, COVID-19, Program, Vernal keratoconjunctivitis, Nasdaq, MMP, Therapy, Institute, Intellectual property, GLOBE, AKC, HIV disease progression rates, Seasonal adjustment, Pharmaceutical industry, Vaccine, Medical device

The article in Allergy summarizes a large body of work undertaken with University College of London and Moorfields Eye Hospital.

Key Points: 
  • The article in Allergy summarizes a large body of work undertaken with University College of London and Moorfields Eye Hospital.
  • MMP shares a similar pathology with bullous pemphigoid where Akari has initiated a Phase III study with nomacopan.
  • Clive Richardson, Chief Executive Officer of Akari, commented, The new surface of the eye data is an important step forward in our program and highlights the potential benefits of nomacopans differentiated bi-specific mode of action.
  • Taken together with prior data this collectively points to the more severe form of these diseases as important clinical targets for nomacopan within the $6bn+ surface of the eye market.